Previous 10 | Next 10 |
Virios Therapeutics (VIRI) announces the dosing of the first patient in its Phase 2b clinical trial evaluating IMC-1 in patients with pain disorder fibromyalgia.Shares up more than 9% premarket.IMC-1 is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir a...
Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today dosing of the first patient in its Phase 2b clinic...
Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that clinical data was highlighted in an oral pres...
Gainers: Onconova Therapeutics (ONTX) +44%.Park City (PCYG) +27%.Agenus (AGEN) +26%.Ultralife (ULBI) +23%.Virios Therapeutics (VIRI) +23%.Lordstown Motors (RIDE) +22%.Aemetis (AMTX) +22%.Aterian (ATER) +21%.Orbital Energy (OEG) +20%.BM Technologies (BMTX) +19%.Losers: Evofem Bioscie...
Virios Therapeutics, Inc. (VIRI) Q1 2021 Earnings Conference Call May 13, 2021 08:30 a.m. ET Company Representatives Greg Duncan - Chief Executive Officer Michael Gendreau - Chief Medical Officer Angela Walsh - Senior Vice President of Finance and Treasurer Ralph Grosswald - Vice President of...
Virios Therapeutics (VIRI): Q1 GAAP EPS of -$0.37.As of March 31, 2021, Virios Therapeutics cash totaled $24.6 million.Press Release For further details see: Virios Therapeutics reports Q1 results
Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the first quarter ended March...
Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Off...
Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its first quarter 2021 financial results will...
Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today announced an interview with Chairman and CEO, Greg Duncan, w...
News, Short Squeeze, Breakout and More Instantly...
Virios Therapeutics Inc. Company Name:
VIRI Stock Symbol:
NASDAQ Market:
Virios Therapeutics Inc. Website:
ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibro...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 37.1% to $0.2344 on volume of 300,511,226 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 78.2% to $1.835 on volume of 218,102,513 shares Greenwave Technology Solutions Inc. (GWAV) r...